In early February, the U.S. Federal Trade Commission published a proposed order that fines telehealth and discount prescription provider GoodRX $1.5 milllion. Though part of the case involves deception — one of two prongs under the FTC Act — the case also raises the first-of-its-kind use of the Health Breach Notification Rule. To help better understand the novel and complex issues embedded in the case, IAPP Editorial Director Jedidiah Bracy, CIPP, caught up with WilmerHale Partner Kirk Nahra, CIPP/US, to discuss some of the takeaways privacy pros in any industry vertical should consider.
Listen Here
10 February 2023
Top takeaways from the FTC-GoodRx case: A chat with Kirk Nahra

Related stories
Hochul enacts New York's AI safety and transparency bill
Notes from the IAPP Canada: 2025 — A year in review
A view from DC: Can the FTC preempt state AI laws?
US House subcommittees explore cybersecurity implications of AI, quantum computing
Notes from the Asia-Pacific region: Insights from IAPP Pan-India KnowledgeNet and Risk GCC

This content is eligible for Continuing Professional Education credits. Please self-submit according to CPE policy guidelines.
